Polycysteine as a new type of radio-protector ameliorated tissue injury through inhibiting ferroptosis in mice.

ABSTRACT: Amifostine has been the only small molecule radio-protector approved by FDA for decades; however, the serious adverse effects limit its clinical use. To address the toxicity issues and maintain the good potency, a series of modified small polycysteine peptides had been prepared. Among them, compound 5 exhibited the highest radio-protective efficacy, the same as amifostine, but much better safety profile. To confirm the correlation between the radiation-protective efficacy and the DNA binding capability, each of the enantiomers of the polycysteine peptides had been prepared. As a result, the L-configuration compounds had obviously higher efficacy than the corresponding D-configuration enantiomers; among them, compound 5 showed the highest DNA binding capability and radiation-protective effi

SUBMITTER: Zhang J 

PROVIDER: S-EPMC7977147 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature